source
- Hemab Therapeutics IPO raises $301.5M, stock triples and funds runway to 2029Hemab Therapeutics completed an upsized $301.5 million IPO in May, boosting total proceeds to $346.7 million. The offering helped the company’s share price climb from $18 at debut to $53.48 by mid‑…
- Infinimmune secures $75 million Series A to develop longer-lasting eczema antibody therapiesInfinimmune, a biotech based in Alameda, California, announced on Tuesday that it has closed a $75 million Series A financing round. The capital will support the development of its first two clinic…